

20<sup>th</sup> November 2019

Hospital Transfusion Committee - Chairs

Dear All,


**RE: Cryo Supernatant Plasma**

I am writing to advise that NZBS will no longer provide Cryo Supernatant Plasma (CSP) as replacement fluid in the treatment of Thrombotic Thrombocytopenic Purpura (TTP). NZBS will continue to provide thawed Fresh Frozen Plasma (FFP) and Fresh Frozen Plasma Extended Life (FFP-EL) upon request.

Various forms of replacement fluids are used in TTP (FFP, CSP, Albumin / FFP mix) and there has been an ongoing international debate over the years as to whether FFP and CSP are equivalent. There is very little in the literature that compares FFP to CSP with respect to improved outcomes although FFP remains the more commonly used replacement fluid. The recently revised 2019 American Society for Apheresis (ASFA) Guideline refers to more recent data again not showing any advantage in using CSP as replacement in TTP.

NZBS data provided indicates that in 2017 there was a significant drop in the amount of CSP being issued and that the number of issues continues to decline. Withdrawal of CSP as a therapeutic component will improve our inventory management and importantly, releases CSP for plasma fractionation.

CSP will be removed from the inventory from the 25<sup>th</sup> November 2019



Kind regards

**DR SARAH MORLEY**  
Chief Medical Officer

cc. *Transfusion Medicine Specialists – NZBS; Transfusion Nurse Specialists – NZBS; National Managers Technical Services – NZBS; Patient Services – NZBS; Blood Processing Team Leaders – NZBS; Rosie Hawes, Technical Support Officer – NZBS Christchurch; Sheryl Khull, Technical Services Support Officer – NZBS Palmerston North*